Frontiers in Aging Neuroscience · Oct 1, 2018

Somatostatin and Neuropeptide Y in Cerebrospinal Fluid: Correlations With Amyloid Peptides Aβ₁₋₄₂ and Tau Proteins in Elderly Patients With Mild Cognitive Impairment

By Duron E, Vidal JS, Grousselle D et al.

A combination of low cerebrospinal fluid (CSF) Amyloid β₁₋₄₂ (Aβ₁₋₄₂) and high Total-Tau (T-Tau) and Phosphorylated-Tau (P-Tau) occurs at a prodromal stage of Alzheimer's disease (AD) and recent findings suggest that network abnormalities and interneurons dysfunction contribute to cognitive deficits. Somatostatin (SOM) and Neuropeptide Y (NPY) are two neuropeptides which are expressed in GABAergic interneurons with different fates in AD the former only being markedly affected. The aim of this study was to analyze CSF SOM, NPY and CSF Aβ₁₋₄₂; T-Tau, P-Tau relationships in 43 elderly mild cognitively impairment (MCI) participants from the Biomarker of AmyLoïd pepTide and AlZheimer's disease Risk (BALTAZAR) cohort. In these samples, CSF SOM and CSF Aβ₁₋₄₂ on the one hand, and CSF NPY and CSF T-Tau and P-Tau on the other hand are positively correlated. CSF SOM and NPY concentrations should be further investigated to determine if they can stand for early AD biomarkers. Clinical Trial Registration: www.ClinicalTrials.gov, identifier #NCT01315639.

doi.org/10.3389/fnagi.2018.00297Open accessPubMed 30327597Biomarkers